Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

The nature of the arena surface affects the outcome of host-finding behavior bioassays in Varroa destructor (Anderson & Trueman).

Piou V, Urrutia V, Laffont C, Hemptinne JL, Vétillard A.

Parasitol Res. 2019 Sep 5. doi: 10.1007/s00436-019-06435-2. [Epub ahead of print]

PMID:
31486946
2.

Simple rules govern the diversity of bacterial nicotianamine-like metallophores.

Laffont C, Brutesco C, Hajjar C, Cullia G, Fanelli R, Ouerdane L, Cavelier F, Arnoux P.

Biochem J. 2019 Aug 9;476(15):2221-2233. doi: 10.1042/BCJ20190384.

PMID:
31300464
3.

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.

Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, Laffont CM, Young M, Jiang J, Liu Z, Learned SM.

Drugs R D. 2019 Sep;19(3):255-265. doi: 10.1007/s40268-019-0277-9.

PMID:
31197606
4.

Control by Metals of Staphylopine Dehydrogenase Activity during Metallophore Biosynthesis.

Hajjar C, Fanelli R, Laffont C, Brutesco C, Cullia G, Tribout M, Nurizzo D, Borezée-Durant E, Voulhoux R, Pignol D, Lavergne J, Cavelier F, Arnoux P.

J Am Chem Soc. 2019 Apr 3;141(13):5555-5562. doi: 10.1021/jacs.9b01676. Epub 2019 Mar 22.

PMID:
30901200
5.

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder.

Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA.

Clin Pharmacol Ther. 2019 Sep;106(3):576-584. doi: 10.1002/cpt.1406. Epub 2019 Apr 8.

PMID:
30801681
6.

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C; RB-US-13-0001 Study Investigators.

Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.

PMID:
30792007
7.

Gibberellins negatively regulate the development of Medicago truncatula root system.

Fonouni-Farde C, Miassod A, Laffont C, Morin H, Bendahmane A, Diet A, Frugier F.

Sci Rep. 2019 Feb 20;9(1):2335. doi: 10.1038/s41598-019-38876-1.

8.

Independent Regulation of Symbiotic Nodulation by the SUNN Negative and CRA2 Positive Systemic Pathways.

Laffont C, Huault E, Gautrat P, Endre G, Kalo P, Bourion V, Duc G, Frugier F.

Plant Physiol. 2019 May;180(1):559-570. doi: 10.1104/pp.18.01588. Epub 2019 Feb 19.

PMID:
30782966
9.

Unraveling new molecular players involved in the autoregulation of nodulation in Medicago truncatula.

Gautrat P, Mortier V, Laffont C, De Keyser A, Fromentin J, Frugier F, Goormachtig S.

J Exp Bot. 2019 Feb 20;70(4):1407-1417. doi: 10.1093/jxb/ery465.

10.

MtNRLK1, a CLAVATA1-like leucine-rich repeat receptor-like kinase upregulated during nodulation in Medicago truncatula.

Laffont C, De Cuyper C, Fromentin J, Mortier V, De Keyser A, Verplancke C, Holsters M, Goormachtig S, Frugier F.

Sci Rep. 2018 Feb 1;8(1):2046. doi: 10.1038/s41598-018-20359-4.

11.

Development and validation of an HPLC-fluorescence method for the quantification of IR780-oleyl dye in lipid nanoparticles.

Varache M, Escudé M, Laffont C, Rustique E, Couffin AC.

Int J Pharm. 2017 Nov 5;532(2):779-789. doi: 10.1016/j.ijpharm.2017.06.019. Epub 2017 Jun 13.

PMID:
28619458
12.

MAP Kinase-Mediated Negative Regulation of Symbiotic Nodule Formation in Medicago truncatula.

Ryu H, Laffont C, Frugier F, Hwang I.

Mol Cells. 2017 Jan;40(1):17-23. doi: 10.14348/molcells.2017.2211. Epub 2017 Jan 31.

13.

Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.

Ivaturi V, Gopalakrishnan M, Gobburu JVS, Zhang W, Liu Y, Heidbreder C, Laffont CM.

Br J Clin Pharmacol. 2017 Jul;83(7):1476-1498. doi: 10.1111/bcp.13246. Epub 2017 Mar 31.

14.

KNAT3/4/5-like class 2 KNOX transcription factors are involved in Medicago truncatula symbiotic nodule organ development.

Di Giacomo E, Laffont C, Sciarra F, Iannelli MA, Frugier F, Frugis G.

New Phytol. 2017 Jan;213(2):822-837. doi: 10.1111/nph.14146. Epub 2016 Sep 1.

15.

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B, Houin G, Laffont CM, Karlsson MO, Friberg LE.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):69-79. doi: 10.1007/s10928-016-9486-9. Epub 2016 Aug 30.

16.

Different Pathways Act Downstream of the CEP Peptide Receptor CRA2 to Regulate Lateral Root and Nodule Development.

Mohd-Radzman NA, Laffont C, Ivanovici A, Patel N, Reid D, Stougaard J, Frugier F, Imin N, Djordjevic MA.

Plant Physiol. 2016 Aug;171(4):2536-48. doi: 10.1104/pp.16.00113. Epub 2016 Jun 24.

17.

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.

Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF.

J Clin Pharmacol. 2016 Jul;56(7):806-15. doi: 10.1002/jcph.665. Epub 2016 Mar 11.

PMID:
26479717
18.

Flavonoids and Auxin Transport Inhibitors Rescue Symbiotic Nodulation in the Medicago truncatula Cytokinin Perception Mutant cre1.

Ng JL, Hassan S, Truong TT, Hocart CH, Laffont C, Frugier F, Mathesius U.

Plant Cell. 2015 Aug;27(8):2210-26. doi: 10.1105/tpc.15.00231. Epub 2015 Aug 7.

19.

The CRE1 cytokinin pathway is differentially recruited depending on Medicago truncatula root environments and negatively regulates resistance to a pathogen.

Laffont C, Rey T, André O, Novero M, Kazmierczak T, Debellé F, Bonfante P, Jacquet C, Frugier F.

PLoS One. 2015 Jan 6;10(1):e0116819. doi: 10.1371/journal.pone.0116819. eCollection 2015.

20.

Local and systemic regulation of plant root system architecture and symbiotic nodulation by a receptor-like kinase.

Huault E, Laffont C, Wen J, Mysore KS, Ratet P, Duc G, Frugier F.

PLoS Genet. 2014 Dec 18;10(12):e1004891. doi: 10.1371/journal.pgen.1004891. eCollection 2014 Dec.

21.

Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.

Pastor ML, Laffont CM, Gladieff L, Chatelut E, Concordet D.

Pharm Res. 2015 Feb;32(2):654-64. doi: 10.1007/s11095-014-1493-1. Epub 2014 Sep 4.

PMID:
25186439
22.

A Medicago truncatula rdr6 allele impairs transgene silencing and endogenous phased siRNA production but not development.

Bustos-Sanmamed P, Hudik E, Laffont C, Reynes C, Sallet E, Wen J, Mysore KS, Camproux AC, Hartmann C, Gouzy J, Frugier F, Crespi M, Lelandais-Brière C.

Plant Biotechnol J. 2014 Dec;12(9):1308-18. doi: 10.1111/pbi.12230. Epub 2014 Jul 24.

23.

Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.

Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF.

J Clin Pharmacol. 2015 Jan;55(1):93-103. doi: 10.1002/jcph.366. Epub 2014 Jul 23.

PMID:
25043337
24.

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs.

Rey JF, Laffont CM, Croubels S, De Backer P, Zemirline C, Bousquet E, Guyonnet J, Ferran AA, Bousquet-Melou A, Toutain PL.

Am J Vet Res. 2014 Feb;75(2):124-31. doi: 10.2460/ajvr.75.2.124.

PMID:
24471748
25.
26.

Bioactive cytokinins are selectively secreted by Sinorhizobium meliloti nodulating and nonnodulating strains.

Kisiala A, Laffont C, Emery RJ, Frugier F.

Mol Plant Microbe Interact. 2013 Oct;26(10):1225-31. doi: 10.1094/MPMI-02-13-0054-R.

27.

Obstetric management does not influence vertical transmission of HCV infection: results of the ALHICE group study.

Delotte J, Barjoan EM, Berrébi A, Laffont C, Benos P, Pradier C, Bongain A; ALHICE study group.

J Matern Fetal Neonatal Med. 2014 May;27(7):664-70. doi: 10.3109/14767058.2013.829813. Epub 2013 Aug 23.

PMID:
23971940
28.

Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Pastor ML, Laffont CM, Gladieff L, Schmitt A, Chatelut E, Concordet D.

Pharm Res. 2013 Nov;30(11):2795-807. doi: 10.1007/s11095-013-1099-z. Epub 2013 Jun 26.

PMID:
23801085
29.

Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology.

Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J.

J Vet Pharmacol Ther. 2013 May 29. doi: 10.1111/jvp.12060. [Epub ahead of print]

PMID:
23713757
30.

Analyzing protein distribution in plant tissues using "whole-mount" immunolocalization.

Bustos-Sanmamed P, Laffont C, Frugier F, Lelandais-Brière C, Crespi M.

Methods Mol Biol. 2013;959:317-22. doi: 10.1007/978-1-62703-221-6_21.

PMID:
23299685
31.

Analyzing small and long RNAs in plant development using non-radioactive in situ hybridization.

Bustos-Sanmamed P, Laffont C, Frugier F, Lelandais-Brière C, Crespi M.

Methods Mol Biol. 2013;959:303-16. doi: 10.1007/978-1-62703-221-6_20.

PMID:
23299684
32.

Two direct targets of cytokinin signaling regulate symbiotic nodulation in Medicago truncatula.

Ariel F, Brault-Hernandez M, Laffont C, Huault E, Brault M, Plet J, Moison M, Blanchet S, Ichanté JL, Chabaud M, Carrere S, Crespi M, Chan RL, Frugier F.

Plant Cell. 2012 Sep;24(9):3838-52. doi: 10.1105/tpc.112.103267. Epub 2012 Sep 28.

33.

Comparative transcriptomic analysis of salt adaptation in roots of contrasting Medicago truncatula genotypes.

Zahaf O, Blanchet S, de Zélicourt A, Alunni B, Plet J, Laffont C, de Lorenzo L, Imbeaud S, Ichanté JL, Diet A, Badri M, Zabalza A, González EM, Delacroix H, Gruber V, Frugier F, Crespi M.

Mol Plant. 2012 Sep;5(5):1068-81. doi: 10.1093/mp/sss009. Epub 2012 Mar 14.

34.

Dual involvement of a Medicago truncatula NAC transcription factor in root abiotic stress response and symbiotic nodule senescence.

de Zélicourt A, Diet A, Marion J, Laffont C, Ariel F, Moison M, Zahaf O, Crespi M, Gruber V, Frugier F.

Plant J. 2012 Apr;70(2):220-30. doi: 10.1111/j.1365-313X.2011.04859.x. Epub 2012 Jan 10.

35.

Characterization of a dual-affinity nitrate transporter MtNRT1.3 in the model legume Medicago truncatula.

Morère-Le Paven MC, Viau L, Hamon A, Vandecasteele C, Pellizzaro A, Bourdin C, Laffont C, Lapied B, Lepetit M, Frugier F, Legros C, Limami AM.

J Exp Bot. 2011 Nov;62(15):5595-605. doi: 10.1093/jxb/err243. Epub 2011 Aug 23.

PMID:
21862482
36.

Transcriptional and post-transcriptional regulation of a NAC1 transcription factor in Medicago truncatula roots.

D'haeseleer K, Den Herder G, Laffont C, Plet J, Mortier V, Lelandais-Brière C, De Bodt S, De Keyser A, Crespi M, Holsters M, Frugier F, Goormachtig S.

New Phytol. 2011 Aug;191(3):647-61. doi: 10.1111/j.1469-8137.2011.03719.x. Epub 2011 Apr 19.

37.

Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.

Khachman D, Conil JM, Georges B, Saivin S, Houin G, Toutain PL, Laffont CM.

J Antimicrob Chemother. 2011 Aug;66(8):1798-809. doi: 10.1093/jac/dkr220. Epub 2011 Jun 8.

PMID:
21653603
38.

Development of a complex parent-metabolite joint population pharmacokinetic model.

Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E.

AAPS J. 2011 Sep;13(3):390-404. doi: 10.1208/s12248-011-9282-9. Epub 2011 May 27.

39.

A new exact test for the evaluation of population pharmacokinetic and/or pharmacodynamic models using random projections.

Laffont CM, Concordet D.

Pharm Res. 2011 Aug;28(8):1948-62. doi: 10.1007/s11095-011-0422-9. Epub 2011 Apr 14.

PMID:
21491150
40.

A case of multifocal chronic Q fever osteomyelitis.

Acquacalda E, Montaudie H, Laffont C, Fournier PE, Pulcini C.

Infection. 2011 Apr;39(2):167-9. doi: 10.1007/s15010-010-0076-2. Epub 2011 Jan 11.

PMID:
21221701
41.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
42.

Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure.

Taylor JA, Vom Saal FS, Welshons WV, Drury B, Rottinghaus G, Hunt PA, Toutain PL, Laffont CM, VandeVoort CA.

Environ Health Perspect. 2011 Apr;119(4):422-30. doi: 10.1289/ehp.1002514. Epub 2010 Sep 20. Review. Erratum in: Environ Health Perspect. 2011 Apr;119(4):429. Toutain, Pierre-Louis [added]; Laffont, Céline M [added].

43.

The compact root architecture1 gene regulates lignification, flavonoid production, and polar auxin transport in Medicago truncatula.

Laffont C, Blanchet S, Lapierre C, Brocard L, Ratet P, Crespi M, Mathesius U, Frugier F.

Plant Physiol. 2010 Aug;153(4):1597-607. doi: 10.1104/pp.110.156620. Epub 2010 Jun 3.

44.

Outcome of exfoliative rejection after isolated intestinal transplantation in an adult: case report.

Yandza T, Schneider SM, Nishida S, Goubaux B, Badan L, Vanbiervliet G, Saint-Paul MC, Bernard G, Laffont C, Gari-Toussaint M, Girard-Pipau F, Miton V, Rahili A, Zeanandin G, Benchimol D, Tzakis A, Gugenheim J, Hébuterne X.

Transplant Proc. 2010 Jan-Feb;42(1):100-2. doi: 10.1016/j.transproceed.2009.12.023.

PMID:
20172289
45.

Evaluation of different tests based on observations for external model evaluation of population analyses.

Brendel K, Comets E, Laffont C, Mentré F.

J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):49-65. doi: 10.1007/s10928-009-9143-7. Epub 2009 Dec 23.

46.

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F.

J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):317-39. doi: 10.1007/s10928-009-9124-x. Epub 2009 Jun 27.

47.

Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera.

Ollier L, Laffont C, Kechkekian A, Doglio A, Giordanengo V.

J Virol Methods. 2008 Dec;154(1-2):206-9. doi: 10.1016/j.jviromet.2008.09.006. Epub 2008 Nov 7.

PMID:
18848582
48.

MicroRNA166 controls root and nodule development in Medicago truncatula.

Boualem A, Laporte P, Jovanovic M, Laffont C, Plet J, Combier JP, Niebel A, Crespi M, Frugier F.

Plant J. 2008 Jun;54(5):876-87. doi: 10.1111/j.1365-313X.2008.03448.x. Epub 2008 Feb 22.

49.

Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentré F, Lemenuel-Diot A, Girard P.

Br J Clin Pharmacol. 2007 Nov;64(5):603-12. Epub 2007 Aug 15. Review.

50.

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentré F.

Clin Pharmacokinet. 2007;46(3):221-34. Review.

Supplemental Content

Loading ...
Support Center